Cerebral Amyloid Angiopathy Vascular Cells is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the cell type. See the content below for detailed information.
Cerebral amyloid angiopathy (CAA) involves amyloid-beta (Aβ) deposition in the walls of cerebral blood vessels. This primarily affects vascular smooth muscle cells (becoming called smooth muscle cells) and pericytes, leading to vessel fragility, hemorrhages, and impaired clearance.
- Aβ40 - Most common in vessels
- Aβ42 - Less common, more aggregative
- Aβ43, Aβ44 - Rare variants
- Leptomeningeal arteries - Most severely
- Cortical arterioles - Common
- Capillaries - Variable involvement
- Veins - Rarely affected
Changes:
- Amyloid replacement of media layer
- Smooth muscle cell loss
- Basement membrane thickening
- Vessel wall fragmentation
Consequences:
- Reduced vascular reactivity
- Increased vessel fragility
- Hemorrhagic risk
- Impaired Aβ clearance
Changes:
- Coverage reduction
- Morphological abnormalities
- Aβ accumulation
- Tight junction alterations
Consequences:
- BBB dysfunction
- Reduced capillary perfusion
- Enhanced Aβ transcytosis impairment
- Neurovascular coupling deficits
Changes:
- Secondary dysfunction
- LRP1 downregulation
- RAGE upregulation
- NO production altered
Consequences:
- Impaired Aβ clearance
- Increased Aβ influx
- Inflammation activation
- Lobar hemorrhages - Cortical bleeds
- Cognitive decline - Vascular cognitive impairment
- Transient focal episodes - "Amyloid spells"
- White matter disease - Leukoaraiosis
- MRI: Lobar microhemorrhages
- SWI: Cortical siderosis
- FLAIR: White matter hyperintensities
- PET: Amyloid binding
- ~80% of AD patients have some CAA
- ApoE ε4 increases CAA risk
- Shared Aβ pathology
- Vascular contribution to dementia
- CAA: Vessels primarily affected
- AD: Parenchymal plaques dominant
- Different Aβ species
- Distinct clinical features
- Antihypertensives - Reduce hemorrhage risk
- Anticoagulant caution - Warfarin avoidance
- Avoid antiplatelets - Bleeding risk
- Aβ immunotherapy - May worsen CAA
- Vascular protective agents - Cerebrolysin
- ApoE targeting - Gene therapy
- Anti-angiogenic therapy - VEGF modulation
The study of Cerebral Amyloid Angiopathy Vascular Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Viswanathan A, Greenberg SM (2011). Cerebral amyloid angiopathy. Annals of Neurology.
- Thal DR, et al. (2008). Cerebral amyloid angiopathy. Nature Reviews Neurology.
- Charidimou A, et al. (2017). Emerging concepts in CAA. Brain.